Forge Therapeutics Raises $15M to Develop First Novel-Gram Negative Antibiotic in Decades
Sandoz Proposed Biosimilars Recommended for Approval in Europe
FDA Allows Novel Inhaled Treatment BIO-11006 to Commence Human Trials in Adults With Lung Cancer
Antibody Delivery Mediated by Recombinant Adeno-Associated Virus
Teva Launches AirDuo Respiclick and Authorized Generic
Parvus Therapeutics, Novartis Partner on Novel Diabetes Nanomedicine
H3 Biomedicine Extends Collaboration with Foundation Medicine to Develop Precision Cancer Therapies
Amgen Announces Expanded Commercial Collaboration with Novartis for Erenumab in Migraine
Blink Health Announces $165M in Financing to Combat High Drug Prices
Blink Health announced that it has raised a $90 million Series B led by 8VC, bringing its total financing to $165 million. 8VC also led Blink Health’s $75 million Series A last year and has been a strong supporter since the company’s inception. Blink Health will use the capital to drive innovations that accelerate the company’s mission…
Arch Biopartners Lead Anti-Bacterial Drug Candidate to Enter Investigator-Sponsored Phase 1 Human Trial
Arch Biopartners, a portfolio-based biotechnology company, announced that the Cincinnati Veterans Affairs Medical Center (CVAMC) will conduct an investigator initiated Phase I human trial to evaluate the safety and pharmacokinetic profile of AB569, the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs. The World Health Organization has declared antibiotic resistance to be…